142 related articles for article (PubMed ID: 24606642)
1. [The effect of tyrosine kinase inhibitor on outcome of allogeneic hematopoietic stem cell transplant for the treatment of chronic myeloid leukaemia].
Xu L; Ma Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):94-5. PubMed ID: 24606642
[No Abstract] [Full Text] [Related]
2. TKIs and transplant for chronic myeloid leukemia.
Litzow MR
Leuk Res; 2010 Feb; 34(2):137-8. PubMed ID: 19651441
[No Abstract] [Full Text] [Related]
3. [The role of allogeneic hematopoietic stem cell transplant in therapy of chronic myeloid leukemia in the era of tyrosine kinase inhibitors].
Liang Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):92-3. PubMed ID: 24606641
[No Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Xu LP; Huang XJ
Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
[No Abstract] [Full Text] [Related]
5. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
Innes AJ; Apperley JF
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
[TBL] [Abstract][Full Text] [Related]
6. Current role of stem cell transplantation in chronic myeloid leukaemia.
Gratwohl A; Heim D
Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
[TBL] [Abstract][Full Text] [Related]
7. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
8. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
Maziarz RT
Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of acute leukemias and chronic myeloid leukemias].
Devergie A
Soins; 2008 Mar; (723):44-5. PubMed ID: 18380312
[No Abstract] [Full Text] [Related]
10. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
[TBL] [Abstract][Full Text] [Related]
11. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
Fernandez HF; Kharfan-Dabaja MA
Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
[TBL] [Abstract][Full Text] [Related]
13. Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?
Eskazan AE; Erdogan I; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Soysal T
Leuk Lymphoma; 2015; 56(10):2995-6. PubMed ID: 25747967
[No Abstract] [Full Text] [Related]
14. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
Irvine DA; Heaney NB; Holyoake TL
Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
[TBL] [Abstract][Full Text] [Related]
15. Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.
Rosti G; Baccarani M
Lancet Oncol; 2005 Sep; 6(9):722-3. PubMed ID: 16161267
[No Abstract] [Full Text] [Related]
16. The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.
Gratwohl A; Baldomero H; Passweg J
Ann Hematol; 2015 Apr; 94 Suppl 2():S177-86. PubMed ID: 25814084
[TBL] [Abstract][Full Text] [Related]
17. Recent advancements in the treatment of chronic myelogenous leukemia.
O'Dwyer ME; Mauro MJ; Druker BJ
Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
[TBL] [Abstract][Full Text] [Related]
18. CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era.
Vaughn JL; Brown S; Papadopoulos EB; Jakubowski AA; Tamari R; Giralt SA; Ponce DM; Cho C; Perales MA; Shaffer BC; Gyurkocza B
Bone Marrow Transplant; 2022 Nov; 57(11):1740-1742. PubMed ID: 36076011
[No Abstract] [Full Text] [Related]
19. Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later.
Max RN; Daniela SB; Moisés M GP; Edgar J HF; Merittzel A MR; María de L PM; Juan C OG; Guillermo J RD; Guillermo J RA
Rev Invest Clin; 2024; 76(2):91-96. PubMed ID: 38740380
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
Hijiya N; Millot F; Suttorp M
Pediatr Clin North Am; 2015 Feb; 62(1):107-19. PubMed ID: 25435115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
